StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RSGK.JK$980.00+1.55%
Fair $980.00+0.0%

RSGK.JK

PT Kedoya Adyaraya Tbk

Healthcare / Medical Care FacilitiesJakarta

$980.00

+15.00 (+1.55%)

Fairly Valued+0.0%Fair Value $980.00Fund rank 32/100 · Data gapFallback financials|
SA 43/C
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 26% · confianza 25%

FCF escenarios

weak_data · normalized FCF $20.2B · quality 59.0/100

Data gap 32/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 43/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

43/100

C

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 4.2%, below the 5% threshold
Thesis & Journal · RSGK.JKLocal privado en este navegador · PT Kedoya Adyaraya Tbk
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$911.1B

P/E

25.6x

↑

EV/EBITDA

14.3x

↑

ROE

4.2%

↑

Gross Margin

31.4%

↓

Debt/Equity

0.03

↓
52-Week Range$980
$860$1560

TradingView lightweight chart

RSGK.JK price, volumen y niveles de valoración

Último $980.00Periodo -54.4%
Fair value: $980.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+9.3%

FCF CAGR

-5.6%

FCF margin

8.4%

FCF / Net income

1.14x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $469.59B · net income $34.51B · FCF $39.44B

2022-FY → 2025-FY

Gross margin

31.4%-5.3% pts

Operating margin

9.6%-1.8% pts

Net margin

7.3%+0.1% pts

FCF margin

8.4%-4.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$469.59B$469.59B$441.07B$373.40B$359.16B
Net Income$34.51B$34.51B$39.69B$25.19B$26.18B
EBITDA$60.98B$60.98B$66.68B$44.61B$57.60B
EPS37.1237.1242.6927.0928.16
Gross Margin31.4%31.4%33.9%33.0%36.7%
Operating Margin9.6%9.6%11.7%7.1%11.4%
Net Margin7.3%7.3%9.0%6.7%7.3%
Balance Sheet
Debt/Equity0.030.03——0.00
Current Ratio1.221.22———
Cash Flow
Free Cash Flow$39.44B$39.44B$20.18B$-6.03B$46.95B
Returns
ROE4.2%4.2%5.0%3.4%3.2%
Valuation
P/E25.5725.5723.6646.5138.71
EV/EBITDA14.2814.2813.2724.9714.59
P/B1.101.101.181.561.24
Growth & Yield
Revenue Growth6.5%6.5%18.1%4.0%—
EPS Growth-13.0%-13.0%57.6%-3.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

32.8%

muy exigente

EPS terminal req.

$86.96

Spread vs growth

-45.9%

5Y implied EPS CAGR

23.2%

exigente

EPS terminal req.

$105.22

Spread vs growth

-36.2%

10Y implied EPS CAGR

16.4%

exigente

EPS terminal req.

$169.46

Spread vs growth

-29.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

23.0x → 26.4x

EPS bridge

42.69 → 37.12

Residual

-2.0%

EPS growth-13.0%
Multiple rerating+15.0%
Dividend+0.0%
Residual / FX / buybacks / cross-term-2.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.